Else Nutrition Announces Highly Anticipated First Commercial Launch of its Groundbreaking Plant-Based Infant Formula in Australia; Also Targeting $50B (USD) Plus Asia Pacific Baby & Child Nutrition Markets - Seite 2

In contrast, current core ingredients in standard infant formulas are ultra-processed, often leading to undesired symptoms. Current dairy formulas, which represent approximately 95% of the market, have shown certain side effects in many infants and their main ingredients are major allergens, with additional concerns related to antibiotics, hormones and other undesired materials, as well as animal welfare and environmental considerations. Moreover, these dairy formula ingredients cannot stay in their whole form due to the need to use fractionated ingredients in order to meet the desired nutritional composition, and they must use highly processed derivatives. Furthermore, soy protein formulas, which account for about 5% of the market, frequently generate similar side effects and contain high levels of phytoestrogens as well as GMOs. Similar to dairy formulas, soy protein formulas cannot stay in their whole form as they require fractionated ingredients in order to meet the required nutritional values. The protein must be isolated and chemically processed with solvents, and the fats and carbohydrates are also considered ultra-processed foods.

Else’s infant formula is free of antibiotics, hormones, pesticides, GMOs, and heavy metals – all of which are an increasing concern among parents. The core ingredients, almonds, buckwheat, and tapioca, have a ~65% lower carbon footprint and require zero chemical processing, keeping proteins intact. The Company’s infant formula is meticulously crafted to support infants aged 6-12 months as they transition to solid foods, ensuring they receive essential nutrients for optimal growth and development.

Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition, stated, “We are extremely proud to officially launch our infant formula and our toddler drink in Australia, serving as a beachhead for the planned global expansion of our range of breakthrough products.

This first-in-class infant product is designed to provide infants with a more nutritious, healthier, and safer alternative.”

“We selected Australia after a meticulous evaluation of the regulatory framework and were deemed in compliance. Australia is widely recognized for its rigorous health and other regulatory standards. In addition, Australia is strategically located in the Asia Pacific region, which we envision will be an ideal market from which to expand our other line of products across the region. The Asia Pacific region represents an extremely large addressable market, desiring safe and high-quality Western products, especially in the children’s health and nutrition categories. Our strategic focus is on establishing partnerships in this region to support our expansion efforts.”